Doxorubicin-Loaded Micelle Targeting MUC1: A Potential Therapeutic for MUC1 Triple Negative Breast Cancer Treatment

Publisher： Bentham Science Publishers

E-ISSN： 1875-5704|15|3|406-416

ISSN： 1567-2018

Source： Current Drug Delivery, Vol.15, Iss.3, 2018-03, pp. : 406-416

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

MUC1 is a Promising Therapeutic Target for Prostate Cancer Therapy

By  

Current Cancer Drug Targets, Vol. 7, Iss. 3, 2007-05 ,pp. : 259-271

Bentham Science Publishers

Access to resources Recommend Favorite

BRCA1-Associated Triple-Negative Breast Cancer and Potential Treatment for Ruthenium-Based Compounds

By  

Current Cancer Drug Targets, Vol. 16, Iss. 7, 2016-08 ,pp. : 606-617

Bentham Science Publishers

Access to resources Recommend Favorite

Potential for novel MUC1 glycopeptide-specific antibody in passive cancer immunotherapy†

By Madsen Caroline B.   Wandall Hans H.   Pedersen Anders Elm  

Immunopharmacology and Immunotoxicology, Vol. 35, Iss. 6, 2013-12 ,pp. : 649-652

Informa Healthcare

Access to resources Recommend Favorite

Insights into the Targeting Potential of Thymoquinone for Therapeutic Intervention Against Triple-negative Breast Cancer

By  

Current Drug Targets, Vol. 19, Iss. 1, 2018-01 ,pp. : 70-80

Bentham Science Publishers

Access to resources Recommend Favorite

Significant Role of MUC1 in Development of Resistance to Currently Existing Anti-cancer Therapeutic Agents

By  

Current Cancer Drug Targets, Vol. 18, Iss. 8, 2018-10 ,pp. : 737-748

Bentham Science Publishers

Access to resources Recommend Favorite